Document is current
Any future updates will be listed below
-
Authors
Wu, Han
Zhang, Jialin
Wang, Qiujie
Li, Zijiao
Li, Linlin
Xie, Ya
-
Funding
Funding for this research was provided by:
Natural Science Foundation of Henan (242300421273, 242300421273, 242300421273, 242300421273, 242300421273, 242300421273)
Henan Province Medical Science and Technology Key Project Jointly Built by the Province and the Ministry (SBGJ202102096, SBGJ202102096, SBGJ202102096, SBGJ202102096, SBGJ202102096, SBGJ202102096)
CSCO-Zai Ding cancer treatment research fund project (Y-zai2022/ms-0246, Y-zai2022/ms-0246, Y-zai2022/ms-0246, Y-zai2022/ms-0246, Y-zai2022/ms-0246, Y-zai2022/ms-0246)
- License Information
-
More Information
Article History
Received: 18 October 2024
Accepted: 17 February 2025
First Online: 19 February 2025
Declarations
:
: The authors declare no competing interests.
: All patient information we use is informed and signed by the patient. The ethical review was examined and certified by the Ethical Review Committee for Research Programs of the First Affiliated Hospital of Zhengzhou University, Ethical Review No. 2022-KY-0740-003, and the ethical review project is entitled “Metabolic reprogramming study in ovarian cancer”. This ethical review was successfully reviewed on June 3, 2022. The experiment was conducted in full compliance with the guidelines of the Ethical Review Committee.
